Literature DB >> 9455523

A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group.

O Karlström1, B Fryklund, K Tullus, L G Burman.   

Abstract

Clostridium difficile-associated diarrhea (CDAD) is regarded as an emerging nosocomial infection. All patients positive for C. difficile in Sweden were recorded during 1995, including primary care patients. Those positive for toxin in feces were defined as CDAD cases. A total of 5,133 CDAD cases were recorded (58 per 100,000 inhabitants per year), as compared with 86 cases diagnosed in 1978 and 553 in 1983. CDAD was almost twice as prevalent as all (combined) diagnosed domestic cases of reportable bacterial and protozoal diarrhea. The age-specific incidence was little affected by gender but increased > 10-fold over the age range of 60-98 years. The differences in overall CDAD incidence were sixfold between counties and threefold between major hospitals. Among hospitalized patients the incidences were highest in geriatric/rehabilitation wards, followed by infectious diseases and internal medicine wards; 28% of all cases involved no recent hospitalization and were defined as community-acquired CDAD.

Entities:  

Mesh:

Year:  1998        PMID: 9455523     DOI: 10.1086/516277

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  48 in total

1.  Clostridium difficile infection in hospitals: a brewing storm.

Authors:  Louis Valiquette; Donald E Low; Jacques Pépin; Allison McGeer
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

2.  Non-steroidal anti-inflammatory drugs and the risk of Clostridium difficile-associated disease.

Authors:  Daniel Suissa; Joseph A C Delaney; Sandra Dial; Paul Brassard
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

3.  Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.

Authors:  T Norén; M Wullt; Thomas Akerlund; E Bäck; I Odenholt; L G Burman
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

4.  Diarrhoea developing in hospital patients.

Authors:  R M McLoughlin; H J O'Connor
Journal:  Ir J Med Sci       Date:  2005 Jan-Mar       Impact factor: 1.568

5.  Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.

Authors:  Olle Aspevall; Annika Lundberg; Lars G Burman; Thomas Akerlund; Bo Svenungsson
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

6.  Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile.

Authors:  Shonna M McBride; Abraham L Sonenshein
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

7.  Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection.

Authors:  L Alcalá; E Reigadas; M Marín; A Martín; P Catalán; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-24       Impact factor: 3.267

8.  Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile.

Authors:  S Karlsson; A Lindberg; E Norin; L G Burman; T Akerlund
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

9.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

10.  Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county.

Authors:  T Norén; T Akerlund; E Bäck; L Sjöberg; I Persson; I Alriksson; L G Burman
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.